RoosterBio has filed a notice of an exempt offering of securities to raise $7 Million in New Equity and Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, RoosterBio is raising up to $7,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Timothy Kelly played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About RoosterBio
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBios products are high-volume, cost-effective, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and cost savings for customers. RoosterBios innovative products and collaborative relationships are ushering in a new era of productivity and standardization into the field.
To learn more about RoosterBio, visit http://www.roosterbio.com/
Contact:
Timothy Kelly, Chief Executive Officer
301-360-3545
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.